Drug Discovery World

APRIL 12, 2023

Evecxia Therapeutics has reported favourable safety, tolerability, pharmacokinetic, and pharmacodynamic data from a Phase I trial of EVX-101 in healthy volunteers treated with escitalopram. The post New adjunctive antidepressant elevates serotonin in Phase I trial appeared first on Drug Discovery World (DDW).

Trials 130

Trials Clinical Pharmacology Medical Schools Pharmacokinetics 130

Drug Discovery World

JULY 20, 2023

Diana Spencer summarises the key messages from the ‘Drug Repurposing: Challenges and Opportunities’ Symposium held at the 19th World Congress of Basic & Clinical Pharmacology (WCP) 2023. Pitceathly argued that interdisciplinary collaboration and good preclinical data is key to successful clinical trials.

Clinical Pharmacology 100

Clinical Pharmacology Clinical Trials Drugs Trials 100

Agency IQ

SEPTEMBER 15, 2023

The committee also made recommendations regarding pharmacokinetic and safety assessments. FDA’s clinical pharmacology analysis challenged previous in vitro estimates of bioavailability for orally administered phenylephrine. Once metabolized, which occurs quickly with a half-life of approximately 1.5

Science 40

Science FDA Clinical Trials Pharmacy 40

Alta Sciences

AUGUST 28, 2023

The trial was performed at Altasciences’ clinical facility in Montréal. The Phase I trial was performed to evaluate safety, tolerability, and pharmacokinetics in a group of 80 healthy participants in a two-part, double-blind, placebo-controlled study. Stern, MD, Chief Medical Officer for Ischemix.

Trials 40

Trials Treatment Clinical Pharmacology Pharmacokinetics 40

Agency IQ

FEBRUARY 23, 2024

I’m not going to say which one is better,” said JIANG LIU, scientific lead at the FDA’s Division of Pharmacometrics in the Office of Clinical Pharmacology. Then, a bit later but still in early-phase studies, developers can leverage this pharmacology information in innovative approaches that may incorporate modeling. . …

Science 40

Science FDA Trials Clinical Pharmacology 40

The Pharma Data

FEBRUARY 8, 2021

Grade 3/4 treatment emergent adverse events (TEAEs) were reported in 63.3 Cerebrovascular and Ischemic Cardiovascular Events — In a randomized study (SPARTAN) of patients with nmCRPC, ischemic cardiovascular events occurred in 4% of patients treated with ERLEADA ® and 3% of patients treated with placebo. percent vs. 3.9

Pharmaceutical Companies 52

Pharmaceutical Companies Treatment Clinical Trials Trials 52